The commercial launch in Germany is part of an exclusive licensing agreement from March 2024, allowing Norgine to market PEDMARQSI in Europe, Australia, and New Zealand. Fennec received an upfront ...

X4 Pharmaceuticals (XFOR) and Norgine announced that they have entered into an exclusive licensing and supply agreement under which Norgine will commercialize mavorixafor in Europe, Australia ...

“We believe Norgine to be the ideal partner due to their impressive infrastructure and successful commercialization track record in specialty pharmaceuticals, as well as a shared focus on ...

RESEARCH TRIANGLE PARK, N.C. - Fennec Pharmaceuticals (NASDAQ:FENC) Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company with a market capitalization of $183 million, announced today that ...

“We believe Norgine to be the ideal partner due to their impressive infrastructure and successful commercialization track record in specialty pharmaceuticals, as well as a shared focus on putting ...

X4 Pharmaceuticals secures €28.5 million upfront and potential €226 million in milestone payments from Norgine for mavorixafor commercialization. X4 Pharmaceuticals has entered an exclusive ...

On January 13, 2025, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced an exclusive licensing and supply agreement with Norgine, a European specialty pharmaceutical company that generates greater ...

When European pharma company Norgine saw an unmet need in how patients were seeking information on one of its brands, they decided to implement a chatbot to help people find the answers they needed.